NCBP1, NCBP2: Cap binding complex
Complex in Homo sapiens that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on NCBP1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Obefazimod | Phase 3 | Abivax | Small molecule | ModulatorCap binding complex modulator | 3 |
| Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation | Obefazimod | Phase 1 | Recruiting | Abivax S.A. | Mar 6, 2026 |
| Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | Obefazimod | Phase 2 | Recruiting | Abivax S.A. | Jun 13, 2024 |
| ABTECT - Maintenance | Obefazimod | Phase 3 | Active, not recruiting | Abivax S.A. | Sep 10, 2022 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4665589, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets